TAIBA-GROUP
taiba Healthcare Group announces setting up “MENAGENE PHARMACEUTICAL INDUSTRIES ” for developing and manufacturing innovative specialty products in the Middle East/North Africa region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604005774/en/
MENAGENE is located in Muscat, Oman (part of GCC countries) and is expected to be operational in the beginning of 2020. It will acquire market authorization rights for the MENA region and provide high quality products and services to all customers and stakeholders in the Middle East. taiba strategic plan consists of an investment on MENAGENE of approx. $50 million and this new strategy strengthens taiba group position in addressing the needs of the Middle East market.
The CEO of taiba group , Dr Saif Al Hasani is strongly committed to bringing access for patients to innovative treatments and cover the high unmet patient needs in the MENA region. He highlights that the key success factors of the company are its cooperation with reputable international partners, its investment on high caliber people, the deep understanding of the specialty and rare disease products and the culture of the stakeholders in the Middle East. taiba commits to invest the needed resources to maximize impact and benefit to patients in the region.
taiba group is a leading healthcare company focusing on niche therapeutic segments including rare diseases and orphan products in the MENA region. taiba has regional HQ in Dubai and logistics hubs in GCC countries and reaches all of the MENA region. taiba is privately held with 130 employees and has had a robust annual growth for over 5 consecutive years with annual sales of $150 million in 2017. taiba’s leading international partners include Alexion, Biomarin, Vertex, Aegerion, Veloxis, etc. and is well known in the therapeutic areas of Hematology/Oncology, Genetics/Metabolics, Transplantation and other Specialty orphan diseases. taiba is able to adapt its business model according to the needs of the partners and in fulfilling the needs of the market.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20180604005774/en/
Contact:
taiba group
Katarina
Ferancova,
+96824442222
Fax:
+96824442200
katarina@taibahealthcare.com
taibame@taibahealthcare.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions19.5.2025 09:29:00 CEST | Press release
GIGABYTE, a global leader in IT and AI infrastructure, is set to showcase its full-stack AI solutions at COMPUTEX 2025 from May 20–23, under the theme “Omnipresence of Computing: AI Forward.” With end-to-end innovations spanning cloud, data center, edge, and application, GIGABYTE is redefining what computing can achieve in the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514218509/en/ GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions Total Data Center Solutions: From Hardware to Cluster Management At the heart of the showcase is GIGAPOD, GIGABYTE’s high-density, rack-scale infrastructure for AI workloads. Integrated with GPM, GIGABYTE’s in-house management platform, the solution enables unified orchestration of resources, from node to rack to cluster. This powerful combination supports rapid deployment, workload optimization, and real-time system monitoring—f
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 08:00:00 CEST | Press release
New GUINNESS WORLD RECORDS Title for Most Accurate Value of Pi - 300 Trillion Digits Calculated Using KIOXIA NVMe™ SSDs Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 08:00:00 CEST | Press release
Businesses using NetApp AIPod can accelerate AI agents and speed up retrieval of relevant information NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data est
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom